This study is testing a new medicine called **VH4524184** to see if it helps treat HIV-1 in adults who haven't had any treatment before. The study compares two doses of VH4524184, taken with the drugs emtricitabine and tenofovir alafenamide (abbreviated as FTC/TAF), against a standard treatment called dolutegravir and lamivudine (abbreviated as DTG/3TC). The goal is to understand how well VH4524184 works over a long time and how to best give it in future studies. ***Key Points:*** - **Study Duration:** Participants will be part of the study for a certain period, but the exact length is not specified here. - **Eligibility:** Only adults 18+ years, with documented HIV-1 infection and a specific health condition, can join. - **Compensation:** The study may offer some form of compensation for participation, but specifics aren't mentioned. Participants cannot be pregnant, breastfeeding, or have certain health conditions like unstable liver disease or cancer. They must also not have been treated with certain medicines recently. The study requires participants to visit the healthcare center for testing and monitoring. Participants must agree to all study requirements and give informed consent to join.